• Alias: EMD1214063
    • Selective inhibitor of MET
    • Currently phase 1 and 2 clinical trials for various solid tumors under investigation
    • Recommended dose: 500 mg orally daily 30 minutes after breakfast
    • Common side effects: Peripheral edema, increased lipase/amylase, nausea/vomiting, fatigue, phototoxicity
    (Falchook et al., 2013)
    Other topics in Targeted and Immunotherapy Agents